Clinical Trial

Castrate Resistant Prostate Cancer Enhertu Therapy

Name: Castrate Resistant Prostate Cancer Enhertu Therapy — clinical trial record (NCT06610825)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CaRPET

Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Use of Enhertu as a Subsequent Line of Therapy in HER2-Positive Metastatic Castration-Resistant Prostate Adenocarcinoma.

Protocol Amendment History 6 amendments

This ClinicalTrials.gov record has been amended 6 times since 2024-09-20; most recent amendment 2026-04-06.

Status change: Not Yet Recruiting → Recruiting 2025-03-12

Trial Details

NCT Number	NCT06610825
Lead Sponsor	Washington D.C. Veterans Affairs Medical Center Collaborators: Daiichi Sankyo, Cancer Research And Biostatistics, Institute for Clinical Research
Conditions	Prostate Cancer Metastatic, Prostate Cancer, CRPC
Enrollment	60 participants
Start Date	2025-03-05
Primary Completion	2027-10 (estimated)
Study Completion	2028-10 (estimated)
Updated on ClinicalTrials.gov	2026-04-13